Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

New Crystal form of Valsartan Dipotassium Salt

발사르탄 이칼륨염의 신규 결정형

  • Seo, Sung-Ki (R&D Center, Kuhnil Pharm. Co., Ltd.) ;
  • Kim, Dae-Duk (Department of Pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Oh, Eui-Chaul (R&D Center, Kuhnil Pharm. Co., Ltd.)
  • Published : 2009.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

A new crystal form of valsartan dipotassium was isolated by recrystallization using the one-pot method. The new crystal form was identified as a monohydrate form ($C_{24}H_{27}N_5O_3K_2.H_2O$) and characterized by diffential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and X-ray powder diffractometry (PXRD). The new crystal data demonstrated to be clearly different from those known for the tetrahydrate form ($C_{24}H_{27}N_5O_3K_2.4H_2O$). It was observed that the monohydrate of vasartan dipotassium salt was completely dissolved in water within 1 hour and its dissolution rate was much faster than anhydrous free form of valsartan.

Keywords

References

  1. L.M. Katrincic, Y. T. Sun, R. A. Carlton, A. M. Diederich, R. L. Mueller and F. G. Vogt, Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system, International Journal of Pharmaceutics, 366, 1-13 (2009) https://doi.org/10.1016/j.ijpharm.2008.08.044
  2. K. Kamada, S. Yoshimura, M. Murata, H. Murata, H. Nagai, H. Ushio and K. Terada, Characterization and monitoring of pseudo-polymorphs in manufacturing process by NIR, International Journal of Pharmaceutics, 368, 103-108 (2009) https://doi.org/10.1016/j.ijpharm.2008.10.010
  3. Y.T. Shon, Pharmaceutical application of polymorphism, Pharmacon, 21, 500-516(1981).
  4. F.W. Langkilde, J. Sjoblom, L. Tekenbergs-Hjelte and J. Mrak, Quantitative FT-Raman analysis of two crystal forms of a pharmaceutical compound, Journal of Pharmaceutical and Biomedical Analysis, 15, 687-696 (1997) https://doi.org/10.1016/S0731-7085(96)01906-1
  5. F. Bayard, C. Decoret and J. Royer, Structural aspects of polymorphism and phase transition in organic molecular crystals, Stud. Phys. Threo. Chem. 69, 211-234 (1990)
  6. N. Kaneniwa, M. Otsuka, T. Yamaguchi, T. Hayashi, K. Hayashi, T. Matsumoto, N. Watari and O. Unezawa, Preparation of polymorphs of some crystalline drug powders, Funsai, 33, 30-40 (1989)
  7. V.M. Rao, R. Sanghvi and H. Zhu, Solubility of Pharmaceutical Solids, Developing Solid Oral Dosage Forms, 1-24 pages (2009)
  8. E.F. Fies and T.A. Hagen, Preformulation. In Theory and Practice of Industrial Pharmacy. Edited by L. Lachman, H. A. Lieberman and J. L. Kanig, Third Edition, Lea and Febiger, 1986 Philadelphia, pp. 171
  9. E.S. Jones, A. Vinh, C.A. McCarthy, T.A. Gaspari and R.E. Widdop, AT2 receptors: Functional relevance in cardiovascular disease, Pharmacology & Therapeutics, 120, 292-316 (2008) https://doi.org/10.1016/j.pharmthera.2008.08.009
  10. C. Lu, Y. Chang, W. Tseng, C. Feng and C. Lu, Analysis of angiotensin II receptor antagonist and protein markers at microliter level plasma by LC-MS/MS, Journal of Pharmaceutical and Biomedical Analysis, 49, 123-128 (2009) https://doi.org/10.1016/j.jpba.2008.09.050
  11. V.A. Ostrovskii, G.I. Koldobskii and R.E. Trifonov, Tetrazoles, Comprehensive Heterocyclic Chemistry III, 257-423 (2008)